← Leaderboards
Roman Manetsch
Medicines For Malaria Venture
$7,151,131
Attributed
$18,519,555
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2011–24$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$18,519,555 · 6
By mechanism
R01$18,052,057 · 5
R21$467,498 · 1
Top collaborators
- Dennis E Kyle15 shared
- James E Kirby7 shared
- R Kiplin Guy5 shared
- Spencer A Knapp5 shared
- Edward W Yu5 shared
- BenoãT Witkowski3 shared
- Jeremy Nicholas Burrows2 shared
- David Waterson2 shared
Others in their field
Top investigators on “Resistance”
- Judith S. Currier · University Of California Los Angeles$243,611,225
- Gregory H Reaman · National Childhood Cancer Foundation$217,720,574
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$180,092,958
- Ralph Parchment · Leidos Biomedical Research, Inc.$149,556,948
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,991,858
- Peter C Adamson · National Childhood Cancer Foundation$113,790,601
Research focus
ResistancePropertyPharmaceutical PreparationsInfectionIn VitroAnalogLeadPlasmodium FalciparumSeriesErythrocytesMalariaNovel TherapeuticsFutureMulti-Drug ResistanceIn Vitro ActivityMetabolicStructureIn VivoScaffoldEvaluationLiverRelapseBloodPrimaquine
Grant awards (28)
Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials$761,258
R01 · FY2024 · AI
Lead optimization and target identification of drugs targeting hypnozoites$649,072
R01 · FY2024 · AI
Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials$766,825
R01 · FY2023 · AI
Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity$701,000
R01 · FY2023 · AI · contact PI
Lead optimization and target identification of drugs targeting hypnozoites$656,698
R01 · FY2023 · AI
Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials$772,231
R01 · FY2022 · AI
Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity$708,550
R01 · FY2022 · AI · contact PI
Lead optimization and target identification of drugs targeting hypnozoites$661,635
R01 · FY2022 · AI
Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials$777,478
R01 · FY2021 · AI
Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity$704,775
R01 · FY2021 · AI · contact PI
Lead optimization and target identification of drugs targeting hypnozoites$680,269
R01 · FY2021 · AI
Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials$818,324
R01 · FY2020 · AI
Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity$713,835
R01 · FY2020 · AI · contact PI
Lead optimization and target identification of drugs targeting hypnozoites$702,238
R01 · FY2020 · AI
Development of Streptothricin Class Antimicrobials as Novel Therapeutics$248,169
R21 · FY2020 · AI · contact PI
Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity$725,226
R01 · FY2019 · AI · contact PI
Development of Streptothricin Class Antimicrobials as Novel Therapeutics$219,329
R21 · FY2019 · AI · contact PI
Validation of New Antimalarial Leads$1,190,932
R01 · FY2015 · AI
Drugs Targeting Erthrocytic and Exoerythrocytic Stages of Malaria$238,402
R01 · FY2015 · GM · contact PI
Validation of New Antimalarial Leads$1,190,932
R01 · FY2014 · AI
Drugs targeting erythrocytic and exoerythrocytic stages of malaria$229,292
R01 · FY2014 · GM · contact PI
Drugs Targeting Erthrocytic and Exoerythrocytic Stages of Malaria$48,655
R01 · FY2014 · GM · contact PI
Validation of New Antimalarial Leads$1,119,476
R01 · FY2013 · AI
Drugs targeting erythrocytic and exoerythrocytic stages of malaria$264,575
R01 · FY2013 · GM · contact PI
Validation of New Antimalarial Leads$1,190,932
R01 · FY2012 · AI
Drugs targeting erythrocytic and exoerythrocytic stages of malaria$274,609
R01 · FY2012 · GM · contact PI
Validation of New Antimalarial Leads$1,238,884
R01 · FY2011 · AI
Drugs targeting erythrocytic and exoerythrocytic stages of malaria$265,954
R01 · FY2011 · GM · contact PI